Danish study of Non-Invasive testing in Coronary Artery Disease 2 (Dan-NICAD 2) is expected to contribute to the improvement of diagnostic strategies for patients suspected of coronary artery disease. In this touchCARDIO interview, we speak with Dr Morten Bøttcher (Aarhus University, Aarhus, Denmark) to discuss the aims and findings of the Dan-NICAD 2 study and the implications for clinical practice.
The abstract entitled ‘DanNICAD-2 – Perfusion scanning with MR or PET after a positive CT coronary angiography’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What were the aims and design of the Dan-NICAD 2 study? (0:16)
- What were the study findings? (1:36)
- How will these findings impact clinical practice? (3:30)
Disclosures: Morten Bøttcher is on the advisory board for Acarix, AstraZeneca, Bayer, Novartis, Novo Nordisk and Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Disease here
